| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/19/2012 | WO2011102655A3 Composition for percutaneous administration of tolterodine with reduced skin irritation |
| 01/19/2012 | WO2011100131A3 Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| 01/19/2012 | WO2011063774A3 Pectin complexes of steroids and pharmaceutical compositions based thereon |
| 01/19/2012 | WO2011034604A9 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| 01/19/2012 | WO2011009852A3 Topical pharmaceutical composition including rel-n- [6 - [ (2r, 6s) - 2, 6 - dimethyl - 4 -morpholinyl] -3 - pyridinyl] - 2 -methyl -41 (trifluoromethoxy) - [1,1' -biphenyl] - 3 - carboxamide |
| 01/19/2012 | WO2010103374A9 Oily suspension containing probiotic bacteria for paediatric uses |
| 01/19/2012 | US20120016467 Polymer-based, sustained release drug delivery system |
| 01/19/2012 | US20120016085 Polymer conjugates |
| 01/19/2012 | US20120016038 Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| 01/19/2012 | US20120015996 Antifungal medicinal compositions |
| 01/19/2012 | US20120015971 Ophthalmic composition comprising ascomycin |
| 01/19/2012 | US20120015893 Formulations containing sorbitan carboxylic acid ester |
| 01/19/2012 | US20120015865 Novel class of cationic lipids for transporting active agents into cells |
| 01/19/2012 | US20120015035 Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists |
| 01/19/2012 | US20120015034 Temperature sensitive polymers |
| 01/19/2012 | US20120014991 Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces |
| 01/19/2012 | US20120014976 Compositions and methods for enhancing immune responses to vaccines |
| 01/19/2012 | US20120014975 Modified single domain antigen binding molecules and uses thereof |
| 01/19/2012 | US20120014935 Recombinant human cln2 protein and methods of its production and use |
| 01/19/2012 | US20120014916 Polyalkylene polymer compounds and uses thereof |
| 01/19/2012 | US20120014873 Peptides whose uptake by cells is controllable |
| 01/19/2012 | CA2805643A1 Targeted nanoparticles for cancer and other disorders |
| 01/19/2012 | CA2805356A1 Composition for the treatment of superficial lesions |
| 01/19/2012 | CA2805228A1 A liquid formulation of long-acting human growth hormone conjugate |
| 01/19/2012 | CA2805222A1 Method and formulations for treating sialic acid deficiencies |
| 01/19/2012 | CA2805203A1 Formulations of 14 - epi -analogues of vitamin d |
| 01/19/2012 | CA2805198A1 Formulations of 14 - epi - analogues of vitamin d and cmc |
| 01/19/2012 | CA2805171A1 Parenteral formulations of elacytarabine derivatives |
| 01/19/2012 | CA2804185A1 Multifunctional antibody conjugates |
| 01/18/2012 | EP2407536A1 ADP-ribosyl transferase fusion variant proteins |
| 01/18/2012 | EP2407178A2 Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
| 01/18/2012 | EP2407176A1 Ameliorating agent for chronic obstructive pulmonary disease |
| 01/18/2012 | EP2407166A1 Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
| 01/18/2012 | EP2407158A1 Ph-responsive liposome |
| 01/18/2012 | EP2407156A2 Aqueous coacervate compositions suitable for making powders and water-soluble formulations of biologically-active agents |
| 01/18/2012 | EP2407155A1 Formulations of 14-epi-analogues of vitamin D |
| 01/18/2012 | EP2407154A1 Formulations of 14-epi-analogues of vitamin D |
| 01/18/2012 | EP2407152A1 Formulations of 14-epi-analogues of vitamin D |
| 01/18/2012 | EP2407151A1 Composition for the treatment of skin and/or nail lesions |
| 01/18/2012 | EP2406273A2 Compound modified by a phosphoramidate and/or phosphonamide group and use thereof |
| 01/18/2012 | EP2405967A2 Implantable device for long-term delivery of drugs |
| 01/18/2012 | EP2405944A1 Prodrugs |
| 01/18/2012 | EP2405943A2 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions |
| 01/18/2012 | EP2405942A1 Oral delivery product |
| 01/18/2012 | EP2405936A1 Injectable biomaterials |
| 01/18/2012 | EP2405934A1 Treatment of diabetes and metabolic syndrome |
| 01/18/2012 | EP2405905A2 Highly compactable and durable direct compression excipients and excipient systems |
| 01/18/2012 | EP2405901A1 Pulsatile release composition of therapeutic agent |
| 01/18/2012 | EP2405898A2 Sustained release composition of therapeutic agent |
| 01/18/2012 | EP2405894A2 Oily suspension containing probiotic bacteria for paediatric uses |
| 01/18/2012 | EP2405892A1 Pharmaceutical formulation comprising ketoprofen and a polyoxyalkylene ester of a hydroxy fatty acid |
| 01/18/2012 | EP2405890A2 Riluzole aqueous suspensions |
| 01/18/2012 | EP2405882A1 Complex of polymeric quaternary ammonium and anionic polymers as a new antimicrobial agent for ophthalmic compositions |
| 01/18/2012 | EP2405758A1 Methods and compositions for liposomal formulation of antigens and uses thereof |
| 01/18/2012 | EP1950294B1 Novel cell penetrating peptide |
| 01/18/2012 | EP1893661B1 Strategies for delivery of active agents using micelles and particles |
| 01/18/2012 | EP1644044B1 Modified antibody fragments |
| 01/18/2012 | EP1617873B1 Treatment of multi-drug resistant tumours by a conjugate of mitomycin C |
| 01/18/2012 | EP1513499B1 Ibuprofen suspension |
| 01/18/2012 | EP1429844B1 Conjugate of perphenazine and gaba and uses thereof |
| 01/18/2012 | EP1360957B1 Vitamin/mineral complex |
| 01/18/2012 | EP1341528B1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 01/18/2012 | EP1292709B1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 01/18/2012 | CN1951962B Polypeptide for preparing antineoplastic antibody and its uses |
| 01/18/2012 | CN102325823A Synthesis of obtaining modified polyethylene glycol intermediates |
| 01/18/2012 | CN102325526A Extended-release pharmaceutical formulations |
| 01/18/2012 | CN102325525A Dermaceutical gel made using sodium fusidate & process to make it |
| 01/18/2012 | CN102321250A Temperature-sensitive amphiphilic cyclodextrin polymer as well as preparation method and application |
| 01/18/2012 | CN102321242A Polyethylene glycol-polylactic acid-poly-L-lysine copolymer, preparation method thereof and application thereof as gene or drug vector |
| 01/18/2012 | CN102321239A Preparation method of water-soluble toluylene compound prodrugs |
| 01/18/2012 | CN102321181A Cyclin D/CDK4 (Cyclin-Dependent Kinase) originated chimeric polypeptide with anti-tumor activity and application as anti-tumor medicament |
| 01/18/2012 | CN102321178A Novel gonadotropin releasing hormone oriented fusion protein mutant |
| 01/18/2012 | CN102321170A Liraglutide variant and conjugate thereof |
| 01/18/2012 | CN102321159A Photosensitizer with tumor targeting and preparation method thereof |
| 01/18/2012 | CN102321158A Polypeptide for preventing cell DNA synthesis and inhibiting cell proliferation and application |
| 01/18/2012 | CN102321140A Lipoid cation function molecule synthesized from natural cholesterol and amino acid and preparation method and application thereof |
| 01/18/2012 | CN102320612A Preparation method and application of fluorescence mesoporous silica nano-particle |
| 01/18/2012 | CN102319486A Method for synchronously controlling shape memory and drug release of drug-carrying shape memory polymer by focused ultrasound |
| 01/18/2012 | CN102319442A Preparation method of core-shell type nanoparticle |
| 01/18/2012 | CN102319441A Preparation method of PLGA swine influenza DNA vaccine microsphere |
| 01/18/2012 | CN102319439A Drug with magnetic microspheres, and use thereof |
| 01/18/2012 | CN102319438A Genistein clathrate compound-containing preparation and its preparation method and use |
| 01/18/2012 | CN102319437A Polymer conjugates of interferon-beta with enhanced biological potency |
| 01/18/2012 | CN102319436A Folic acid-modified O-carboxymethyl chitosan-deoxycholic acid complex and preparation method and application thereof |
| 01/18/2012 | CN102319435A Mesoporous silica compound particles containing gold nanorods, preparation method and application thereof |
| 01/18/2012 | CN102319434A Application of ultrasound in intelligent controlled release of medicament coated by temperature sensitive material |
| 01/18/2012 | CN102319432A Ocular implant made by a double extrusion process |
| 01/18/2012 | CN102319430A Antibody formulations in histidine-acetate buffer |
| 01/18/2012 | CN102319428A Glycosylceramide adjuvant for saccharide antigens |
| 01/18/2012 | CN102319418A Buserelin preparation and preparation method thereof |
| 01/18/2012 | CN102319357A Lipid-lowering dispersible tablets and preparation technology thereof |
| 01/18/2012 | CN102319344A Rhizoma paridis total saponin solid dispersion and preparation method thereof |
| 01/18/2012 | CN102319294A Double-vanilla preparation and preparation method thereof |
| 01/18/2012 | CN102319266A krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 01/18/2012 | CN102319257A Sulfate liquid preparation |
| 01/18/2012 | CN102319231A Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 01/18/2012 | CN102319230A Implantable 5-fluorouracil sustained and controlled release delivery system and preparation method thereof |
| 01/18/2012 | CN102319228A Dutasteride liquid hard capsule and preparation method thereof |
| 01/18/2012 | CN102319227A Lomerizine hydrochloride osmotic pump tablet and preparation method thereof |
| 01/18/2012 | CN102319225A Trimetazidine hydrochloride sustained release tablet and preparation method thereof |